

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2496)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (“**Director(s)**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) announces that Dr. Dai Weiguo (“**Dr. Dai**”) has tendered his resignation as an independent non-executive Director and a member of the nomination committee of the Board (the “**Nomination Committee**”) in order to devote more time to his other personal commitments. Dr. Dai’s resignation will take effect from July 30, 2024 in accordance with the Company Law of the People’s Republic of China and other relevant laws and regulations, and the articles of association of the Company.

Dr. Dai has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company.

The Board would like to express its sincere gratitude to Dr. Dai for his valuable contribution to the Company during his tenure of service.

NON-COMPLIANCE WITH THE LISTING RULES

Immediately following the resignation of Dr. Dai as an independent non-executive Director and a member of the Nomination Committee, the Company fails to have a majority of independent non-executive Directors in the Nomination Committee as required under Rule 3.27A of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

The Company will use its best endeavours to identify a suitable candidate to fill the required vacancy as soon as practicable in order to meet the aforementioned Listing Rules requirements. Further announcement(s) will be made by the Company as and when appropriate.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
*Chairman of the Board, Executive
Director and Chief Executive Officer*

Wuhan, PRC, July 30, 2024

As of the date of this announcement, the Board comprises Dr. Zhou Pengfei as executive Director, Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Dr. Guo Hongwei and Mr. Xie Shouwu as non-executive Directors, and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.